Advanced Search

Submit Manuscript

Volume 32, No 6, Jun 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 6, June 2022: 505-506

RESEARCH HIGHLIGHTS

Amplifying natural antitumor immunity for personalized immunotherapy

Laura K. Donovan1,* , Michael D. Taylor2

1Great Ormond Street Institute of Child Health, University College London, London, UK
2The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON, Canada
Correspondence: Laura K. Donovan(l.k.donovan@ucl.ac.uk)

T-cells engineered with T-cell receptors (TCR-T), chimeric antigen receptor (CAR) T-cells, and neoantigen vaccines have each demonstrated therapeutic success in clinical trials, but many of these therapies can only benefit a small group of patient types owing to the restriction of certain tumor-associated antigens; personalized immunotherapy customizes cancer treatments to each patient, achieving greater responses without damaging normal tissues. In a recent Cell Research paper, He et al. show that TCR-T cells engineered with TCRs from naturally occurring tumor antigen-specific (Tas) T-cells are an effective therapy against non-small cell lung carcinoma, and a promising agent for future immunotherapies.


https://doi.org/10.1038/s41422-022-00649-3

FULL TEXT | PDF

Browse 457